Loxo Oncology To Present At The Stifel 2016 Healthcare Conference

STAMFORD, Conn., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the Stifel 2016 Healthcare Conference on November 15, 2016 at 11:00AM ET in New York City.

A live webcast of the presentation will be available at http://ir.loxooncology.com/.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.

Company:Jacob S. Van NaardenChief Business Officer jake@loxooncology.com

Investors:Peter RahmerThe Trout Group, LLC646-378-2973 prahmer@troutgroup.com

Media:Dan BudwickPure Communications, Inc.973-271-6085 dan@purecommunicationsinc.com

If you liked this article you might like

Nucor, Henry Schein, Kemet, Splunk: 'Mad Money' Lightning Round

Nucor, Henry Schein, Kemet, Splunk: 'Mad Money' Lightning Round

Give Thanks for This Week: Cramer's 'Mad Money' Recap (Tuesday 11/21/17)

Give Thanks for This Week: Cramer's 'Mad Money' Recap (Tuesday 11/21/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

Biotech Movers: Loxo, NewLink, BioCryst

Biotech Movers: Loxo, NewLink, BioCryst